Imprivata (IMPR) Tops Q4 EPS by 1c, Offers Q1 & FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Imprivata (IMPR) Tops Q4 EPS by 1c, Offers Q1 & FY Guidance
February 17, 2016 11:53 AM EST
Piper Jaffray analyst, Sean Wieland, reiterated his Overweight rating on Imprivata (NYSE: IMPR) but cut his PT by $1 as the company posted a mostly in line quarter. The company continues its transition out of the non-hospital markets to focus on its core base but as multiples tighten, the PT pulled back slightly, despite the solid results.
Revenues of $34.2M beat consensus of $33.2M, and non-GAAP EPS of ($0.15) was in line with consensus. Product revenue of $19.9M grew by 20% y/y... More
February 17, 2016 7:05 AM EST
Leerink Partners maintained an Outperform rating on Imprivata (NYSE: IMPR), and cut the price target to $13.00 (from $17.00), following the company's 4Q earnings report. Imprivata reported revenue of $34.2m in the quarter, slightly above guidance of $32-34m. Adjusted EPS for the quarter came in at ($0.09),... More
